



Malmö 20 May 2025

PRESS RELEASE

Aptahem receives strong interest in partnership from a European pharmaceutical company

Aptahem AB (publ), a biotechnology company developing RNA-based therapies for serious inflammatory conditions, announces today that the company has received a formal expression of interest from a well-reputed European pharmaceutical company with interest in Aptahem's innovation platform.

After an extended period of constructive dialogue, the European company has expressed in writing a strong interest in pursuing discussions and entering into a potential partnership with Aptahem. The expressed interest relates to the company's innovative lead candidate Apta-1 with regard mainly to anti-inflammatory properties.

The ongoing dialogue is currently focusing on key areas of agreement such as specific disease indications and large-scale production of Apta-1.

CEO Mikael Lindstam comments:

"This is an important step for Aptahem. After an extended period of consideration, a major player in the pharmaceutical industry has expressed a clear interest in taking the next step towards a partnership, which is a strong recognition of our technology. It further strengthens our position for future milestones."

Aptahem continues to pursue its partner strategy with the aim of optimizing the development and commercial value of Apta-1.

For further information:

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.